

'Migril' : ergotamine compound tablets.

Contributors

Burroughs Wellcome and Company

Publication/Creation

1968.

Persistent URL

<https://wellcomecollection.org/works/ppz3hhdv>

License and attribution

Conditions of use: it is possible this item is protected by copyright and/or related rights. You are free to use this item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).

**wellcome
collection**

Wellcome Collection
183 Euston Road
London NW1 2BE UK
T +44 (0)20 7611 8722
E library@wellcomecollection.org
<https://wellcomecollection.org>



'Migril'

Ergotamine Compound Tablets.

Indications

'Migril' is indicated for the symptomatic treatment of migraine.

Dosage

1 to 2 tablets at the first warning of an attack, followed by $\frac{1}{2}$ or 1 tablet at hourly or half-hourly intervals, if required. The smallest effective dose should be chosen. Not more than 4 tablets should be taken during any single attack, or more than 12 tablets in any one week. Children should be given proportionately less.

Contra-indications and Side-effects

'Migril' is contra-indicated in peripheral vascular disease, angina pectoris, kidney and liver diseases, pregnancy and febrile conditions. Rarely there may be undue sensitivity to ergotamine; if, therefore, a patient under treatment feels a sensation of coldness or aching in his extremities, he should take no more of the tablets. Side-effects include abdominal pain or fatigue in the limbs.

Presentation

'Migril' brand Ergotamine Compound, scored compression-coated tablets containing:

Ergotamine tartrate, 2 mg. Cyclizine hydrochloride, 50 mg.

Caffeine hydrate, 100 mg.

Basic cost to N.H.S.: 6s. 11d. for 10 tablets.

Additional information is available on request.



Burroughs Wellcome & Co. (The Wellcome Foundation Ltd.) London

7954a(H) Printed in England Jan 68-32 A